Completed PHASE2 INTERVENTIONAL 1-arm NCT01031420

Dose Dense MVAC for Muscle Invasive Bladder Cancer

Phase II Trial of Neoadjuvant Dose Dense MVAC in Muscle Invasive Bladder Cancer and High Risk Urothelial Carcinoma of the Upper Urinary Tract

Sponsor: Fox Chase Cancer Center

Conditions High Risk Urothelial Carcinoma of the Upper Urinary Tracts Muscle Invasive Bladder Cancer

Interventions single arm dose dense MVAC

Updated 10 times since 2017 Last updated: Aug 28, 2019 Started: Dec 7, 2009 Primary completion: Jul 19, 2013 Completion: Aug 7, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01031420, this PHASE2 trial focuses on High Risk Urothelial Carcinoma of the Upper Urinary Tracts and Muscle Invasive Bladder Cancer and remains completed. Sponsored by Fox Chase Cancer Center, it has been updated 10 times since 2009, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 5 earlier versions

Oct 2019 — Jan 2021 [monthly]

Completed PHASE2
Sep 2019 — Oct 2019 [monthly]

Completed PHASE2
Jun 2018 — Sep 2019 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fox Chase Cancer Center

Data source: Fox Chase Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Philadelphia, United States